Bifalgorithm post

And the B two twelveers over aspirin in 2023. I'm Herb, the heart pharmacist, and on this channel I review the most up-to-date and evidence-based information on heart medications and supplements. Capri was published in Lana in 1996. They found that clopirel had an annual 5.3 two percent risk reduction of the primary endpoint compared to 5.8 three percent with aspirin, with a small relative risk reduction of only 8.7 percent in favor of clopidiggral, which if you do some simple math, is only roughly a zero 0.5 percent absolute risk reduction. The problem that I have with including the CAPRI trial in the meta-analysis was that it was done in an era where a lot of people were not actually on great medical therapy, including high potency statins. I suspect that the difference between clopidgral and aspirin may even be less significant, with people being on better statins these days. Say no to drugs.

And the B two twelveers over aspirin in 2023. I'm Herb, the heart pharmacist, and on this channel I review the most up-to-date and evidence-based information o…